Assessment of safety and efficacy of KabasuraKudineer in mild to moderate COVID-19
Phase 2
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2020/08/026985
- Lead Sponsor
- Chettinad Hospital and Research Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
a.COVID-19 positive patients with mild to moderate disease.
b.Males and females aged between 18 and 60 years who are admitted in Chettinad Hospital and Research Institute
c.Patients willing to give written informed consent.
Exclusion Criteria
a.Patients Suffering from Chronic diseases- hepatic, renal, Hypertension and Diabetes mellitus
b.Pregnancy & lactation
c. Severe COVID-19
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Time to Negative conversion of SARS CoV-2 <br/ ><br>2.Time to symptom resolution <br/ ><br>3.Reduction in Viral load (0,4,7 days) <br/ ><br> <br/ ><br>Timepoint: 4,7 days
- Secondary Outcome Measures
Name Time Method 1. Progression to severe ARDS <br/ ><br>2. Adverse effects/eventsTimepoint: 7 days